獸醫分子診斷市場機會、成長動力、產業趨勢分析及 2025 - 2034 年預測

2024年，全球獸醫分子診斷市場規模達6.478億美元，預計2034年將以7.9%的複合年成長率成長至14億美元。動物傳染病發病率的不斷上升推動了這個市場的穩定成長，也增加了對更準確、更及時診斷方法的需求。隨著全球尤其是城市地區寵物擁有量的持續成長，對早期疾病檢測的重視程度也日益加深。寵物照護文化的這種轉變正鼓勵人們投資於能夠提供快速、可靠和非侵入性解決方案的分子診斷工具。獸醫醫療基礎設施的改善，例如現代化診斷實驗室和技術先進的設施的出現，正在進一步加速市場成長。此外，寵物保險的作用日益增強，使得更廣泛的寵物主人群體能夠更容易獲得複雜的診斷程序。

推動這一市場發展的另一個主要因素是全球對預防人畜共患疾病傳播的重視程度不斷提高，尤其是在伴侶動物和牲畜疫情爆發風險日益增加的情況下。多個國家的監管機構正在實施更嚴格的動物健康和疾病監測政策，這為獸醫分子診斷的應用創造了更有利的環境。政府主導的旨在改善食品安全和動物健康的健康計畫進一步加強了控制疾病傳播的力度，從而刺激了對精準診斷工具的需求。包括先進分子檢測平台在內的獸醫技術創新正在重新定義動物疾病管理策略方面發揮關鍵作用。將這些工具整合到常規獸醫實踐中，不僅可以提高診斷的準確性，還可以加快治療決策，從而改善整體療效。

依產品細分，市場可分為試劑盒、試劑和儀器。試劑盒和試劑佔據主導地位，2024 年的估值為 4.507 億美元。與儀器不同，這些耗材用於每項檢測，因此其需求會隨著獸醫檢測總量的成長而不斷成長。它們在診斷工作流程中的持續使用確保了製造商和供應商穩定的收入來源，使其成為整個市場的最大貢獻者。

就技術而言，市場包括DNA定序、PCR、微陣列和等溫核酸擴增技術 (INAAT) 試劑盒。 PCR 細分市場在 2024 年佔據了最大的收入佔有率，佔整個市場的 66.2%。 PCR 檢測因其速度快、準確度高、靈敏度高，能夠檢測多種病原體而備受青睞。這些檢測能夠在早期階段識別傳染病，這對於疾病的預防和控制至關重要。即時 PCR 和多重 PCR 等創新技術使得在一次檢測中即可檢測多種病原體，從而簡化了診斷流程並提高了實驗室效率。

根據應用，該市場涵蓋傳染病、遺傳性疾病和其他用途。傳染病細分市場收入最高，2024年達3.286億美元，預計到2034年複合年成長率將達8.3%。全球動物族群的高疾病負擔使得傳染病診斷成為一個主要關注領域，尤其是在人們對疾病傳播和跨物種感染的認知不斷提高的情況下。

依動物類型，市場分為伴侶動物和家畜。伴侶動物市場佔據主導地位，2024年收入達4.163億美元，預計2034年將達到9.011億美元。此細分市場的強勁成長與寵物擁有量的激增和動物照護支出的增加息息相關。可支配收入的增加以及對寵物情感依附的加深，推動了對高階醫療服務的需求，包括早期精準的診斷。

從最終用途來看，診斷實驗室預計將實現強勁成長，預計2025年至2034年的複合年成長率為7.6%。這些實驗室憑藉其完善的基礎設施、高技能的員工隊伍以及處理大量高精度檢測的能力，成為獸醫診斷生態系統中不可或缺的參與者。它們通常是複雜分子檢測的首選，並可作為缺乏內部檢測能力的小型診所和獸醫診所的中央檢測設施。

從區域來看，北美引領全球獸醫分子診斷市場，2024年市場規模達3.19億美元，預計2034年將達到6.857億美元。這一成長得益於該地區寵物飼養的普及、動物健康意識的提升以及強大的醫療基礎設施。 2024年，美國在該區域市場的佔有率達到2.913億美元，凸顯了其在全球市場的主導地位。

市場仍然保持中等程度的分散，領先的製藥和生物技術公司透過創新和策略擴張來保持競爭優勢。碩騰、愛德士實驗室、凱傑和紐勤等主要參與者合計佔全球市場收入的48%-50%。這些公司正在不斷改進其診斷平台，以提供更先進、更具成本效益的解決方案。同時，許多區域性公司透過提供經濟實惠的產品並透過併購和產品創新進行擴張，加劇了競爭。

目錄

第1章：方法論與範圍

第2章：執行摘要

第3章：行業洞察

• 產業生態系統分析
  • 供應商格局
  • 每個階段的增值
  • 影響價值鏈的因素
• 產業衝擊力
  • 成長動力
    • 伴侶動物的收養率不斷上升
    • 人畜共通傳染病高發
    • 獸醫分子診斷技術的進展
    • 寵物保險的普及率不斷提高
  • 產業陷阱與挑戰
    • 動物試驗成本高
    • 缺乏熟練的人員
  • 機會
    • 技術進步和即時診斷分子工具
    • 畜牧業的擴張和對食品安全的需求
• 成長潛力分析
• 監管格局
• 技術格局
  • 當前的技術趨勢
  • 新興技術
• 2024年各國獸醫數量
• 定價分析
• 未來市場趨勢
• 波特的分析
• PESTEL分析

第4章：競爭格局

• 介紹
• 公司市佔率分析
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 關鍵進展
  • 併購
  • 夥伴關係與協作
  • 新產品發布
  • 擴張計劃

第5章：市場估計與預測：按產品，2021 年至 2034 年

• 主要趨勢
• 試劑盒和試劑
• 儀器

第6章：市場估計與預測：按技術，2021 年至 2034 年

• 主要趨勢
• 聚合酶連鎖反應
  • 即時PCR
  • 其他PCR
• DNA定序
• 微陣列
• INAAT 試劑盒

第7章：市場估計與預測：按應用，2021 年至 2034 年

• 主要趨勢
• 傳染病
  • 細菌性傳染病
  • 病毒性傳染病
  • 寄生蟲感染疾病
  • 其他傳染病
• 遺傳疾病
• 其他應用

第8章：市場估計與預測：依動物類型，2021 年至 2034 年

• 主要趨勢
• 伴侶動物
  • 狗
  • 貓
  • 馬匹
  • 其他伴侶動物
• 牲畜
  • 牛
  • 豬
  • 家禽
  • 其他牲畜

第9章：市場估計與預測：依最終用途，2021 年至 2034 年

• 主要趨勢
• 診斷實驗室
• 獸醫診所
• 獸醫院
• 其他最終用途

第10章：市場估計與預測：按地區，2021 年至 2034 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 義大利
  • 西班牙
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：公司簡介

• Agrolabo
• bioMerieux
• BIONOTE
• Bioneer Corporation
• Bio-Rad Laboratories
• GZ MED
• Heska Corporation
• Idexx Laboratories
• INDICAL BIOSCIENCE
• Innovative Diagnostics
• Neogen Corporation
• QIAGEN
• Thermo Fisher Scientific
• Veterinary Molecular Diagnostics
• Zoetis

The Global Veterinary Molecular Diagnostics Market was valued at USD 647.8 million in 2024 and is estimated to grow at a CAGR of 7.9% to reach USD 1.4 billion by 2034. This steady expansion is being driven by a growing incidence of infectious diseases in animals, which has heightened the demand for more accurate and timely diagnostic methods. As pet ownership continues to rise globally, especially in urban regions, the emphasis on early disease detection is also increasing. This shift in pet care culture is encouraging investment in molecular diagnostic tools that offer fast, reliable, and non-invasive solutions. Improvements in veterinary healthcare infrastructure, such as the presence of modern diagnostic labs and technologically advanced facilities, are further accelerating market growth. In addition, the growing role of pet insurance is making sophisticated diagnostic procedures more accessible to a broader base of pet owners.

Another major factor fueling this market is the heightened global focus on preventing zoonotic disease transmission, particularly with the increasing risk of outbreaks affecting both companion and livestock animals. Regulatory authorities across several countries are enforcing stricter policies on animal health and disease surveillance, which has created a more supportive environment for the adoption of veterinary molecular diagnostics. Government-led wellness programs aimed at improving food safety and animal health have further intensified efforts to control disease spread, boosting demand for precise diagnostic tools. Technological innovations in veterinary medicine, including advanced molecular testing platforms, are playing a key role in redefining disease management strategies for animals. The integration of these tools into routine veterinary practices not only improves the accuracy of diagnostics but also enables faster treatment decisions, improving overall outcomes.

By product, the market is segmented into kits and reagents and instruments. Kits and reagents dominated the product landscape with a valuation of USD 450.7 million in 2024. Unlike instruments, these consumables are used in every test, creating recurring demand that scales with the overall volume of veterinary testing. Their consistent usage in diagnostic workflows ensures a stable revenue stream for manufacturers and suppliers, making them the largest contributor to the overall market.

In terms of technology, the market includes DNA sequencing, PCR, microarrays, and isothermal nucleic acid amplification technology (INAAT) kits. The PCR segment held the largest revenue share in 2024, accounting for 66.2% of the total market. PCR testing is preferred due to its speed, accuracy, and sensitivity in detecting a wide range of pathogens. These tests are capable of identifying infectious diseases in their earliest stages, which is essential for disease prevention and control. Innovations such as real-time PCR and multiplex PCR allow multiple pathogens to be detected in a single test, which streamlines the diagnostic process and improves laboratory efficiency.

Based on application, the market covers infectious diseases, genetic disorders, and other uses. The infectious diseases segment recorded the highest revenue, reaching USD 328.6 million in 2024, and is projected to grow at a CAGR of 8.3% through 2034. The high disease burden across animal populations globally has made infectious disease diagnostics a major focus area, especially with increasing awareness of disease transmission and cross-species infections.

On the basis of animal type, the market is divided into companion animals and livestock animals. Companion animals led the market with revenue of USD 416.3 million in 2024 and are expected to reach USD 901.1 million by 2034. The strong growth of this segment is linked to the surge in pet ownership and increased spending on animal care. Rising disposable income and greater emotional attachment to pets are pushing demand for premium healthcare services, including early and accurate diagnostics.

By end use, diagnostic laboratories are poised for strong growth, with an expected CAGR of 7.6% between 2025 and 2034. These labs are essential players in the veterinary diagnostics ecosystem due to their infrastructure, skilled workforce, and ability to handle high volumes of testing with exceptional precision. They are often the preferred choice for complex molecular testing and serve as central testing facilities for smaller clinics and veterinary practices that lack in-house capabilities.

Regionally, North America leads the global veterinary molecular diagnostics market, with a market size of USD 319 million in 2024 and a projected value of USD 685.7 million by 2034. This growth is supported by widespread pet ownership, increased awareness about animal health, and strong healthcare infrastructure across the region. The U.S. accounted for USD 291.3 million of the regional market in 2024, underscoring its dominant position in the global landscape.

The market remains moderately fragmented, with leading pharmaceutical and biotech firms holding a competitive edge through innovations and strategic expansions. Key players such as Zoetis, IDEXX Laboratories, Qiagen, and Neogen Corporation collectively account for 48%-50% of global revenue. These companies are consistently enhancing their diagnostic platforms to offer more advanced and cost-effective solutions. At the same time, numerous regional firms are intensifying competition by offering budget-friendly products and expanding through mergers, acquisitions, and product innovation.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Regional
  • 2.2.2 Product
  • 2.2.3 Technology
  • 2.2.4 Application
  • 2.2.5 Animal type
  • 2.2.6 End use
• 2.3 CXO perspectives: Strategic imperatives
  • 2.3.1 Key decision points for industry executives
  • 2.3.2 Critical success factors for market players
• 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
  • 3.1.1 Supplier landscape
  • 3.1.2 Value addition at each stage
  • 3.1.3 Factors affecting the value chain
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising adoption of companion animals
    • 3.2.1.2 High prevalence of zoonotic diseases
    • 3.2.1.3 Advancements in veterinary molecular diagnostics technologies
    • 3.2.1.4 Increasing adoption of pet insurance
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost associated with animal tests
    • 3.2.2.2 Lack of skilled personnel
  • 3.2.3 Opportunities
    • 3.2.3.1 Technological advancements and point-of-care molecular tools
    • 3.2.3.2 Expanding livestock industry and demand for food safety
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
  • 3.4.4 Latin America
  • 3.4.5 Middle East and Africa
• 3.5 Technology landscape
  • 3.5.1 Current technological trends
  • 3.5.2 Emerging technologies
• 3.6 Number of veterinarians, by country, 2024
• 3.7 Pricing analysis
• 3.8 Future market trends
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Merger and acquisition
  • 4.6.2 Partnership and collaboration
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Kits and reagents
• 5.3 Instruments

Chapter 6 Market Estimates and Forecast, By Technology, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 PCR
  • 6.2.1 Real time PCR
  • 6.2.2 Other PCR
• 6.3 DNA sequencing
• 6.4 Microarray
• 6.5 INAAT kits

Chapter 7 Market Estimates and Forecast, By Application, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Infectious diseases
  • 7.2.1 Bacterial infectious diseases
  • 7.2.2 Viral infectious diseases
  • 7.2.3 Parasitic infectious diseases
  • 7.2.4 Other infectious diseases
• 7.3 Genetic diseases
• 7.4 Other applications

Chapter 8 Market Estimates and Forecast, By Animal Type, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Companion animals
  • 8.2.1 Dogs
  • 8.2.2 Cats
  • 8.2.3 Horses
  • 8.2.4 Other companion animals
• 8.3 Livestock animals
  • 8.3.1 Cattle
  • 8.3.2 Swine
  • 8.3.3 Poultry
  • 8.3.4 Other livestock animals

Chapter 9 Market Estimates and Forecast, By End Use, 2021 – 2034 ($ Mn)

• 9.1 Key trends
• 9.2 Diagnostic laboratories
• 9.3 Veterinary clinics
• 9.4 Veterinary hospitals
• 9.5 Other end use

Chapter 10 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Italy
  • 10.3.5 Spain
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 UAE

Chapter 11 Company Profiles

• 11.1 Agrolabo
• 11.2 bioMerieux
• 11.3 BIONOTE
• 11.4 Bioneer Corporation
• 11.5 Bio-Rad Laboratories
• 11.6 GZ MED
• 11.7 Heska Corporation
• 11.8 Idexx Laboratories
• 11.9 INDICAL BIOSCIENCE
• 11.10 Innovative Diagnostics
• 11.11 Neogen Corporation
• 11.12 QIAGEN
• 11.13 Thermo Fisher Scientific
• 11.14 Veterinary Molecular Diagnostics
• 11.15 Zoetis